MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies
Researchers at MD Anderson have a new partner to help them get early-stage programs into the clinic.
In conjunction with The Focus Fund, MD Anderson is launching the Cancer Focus Fund to advance investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials. The fund will start off with more than $50 million of initial capital.
“Without appropriate support, we know that some therapies with great potential may be delayed, may not be developed properly in the clinical setting or may never make it into clinical studies,” MD Anderson senior VP Ferran Prat said in a statement. “Through investment from the Cancer Focus Fund and the support of MD Anderson, we hope to advance worthwhile new treatments past the traditional hurdles in the drug development process.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.